生物活性

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4].

IC₅₀ & Target

IL-6

體外研究
(In Vitro)

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression
in SAS cells with serum-free medium[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Concentration:

1 ng/mL, 10 ng/mL, and 100 ng/mL

Incubation Time:

24 hours, 48 hours

Result:

Inhibited the IL-6R expressed on human-derived HARA-B cells.

Cell Cytotoxicity Assay[1]

Cell Line:

Ba/F3-gp130-IL-6R cells

Concentration:

0.001–10000 μg/ml

Incubation Time:

2 days

Result:

Inhibited Ba/F3-gp130-IL-6R cell proliferation.

Western Blot Analysis[3]

Cell Line:

SAS cells

Concentration:

1 μM

Incubation Time:

6 hours

Result:

Reduced the phosphorylation of STAT3.

RT-PCR[3]

Cell Line:

SAS cells

Concentration:

1-5 μM

Incubation Time:

24 hours

Result:

Reduced VEGF mRNA expression.

體內研究
(In Vivo)

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL;
twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;
100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]

Dosage:

1.0 mg/100 μL

Administration:

Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks

Result:

Led the volume of each metastatic focus significantly smaller.

Animal Model:

SCID mice with SAS cells[3]

Dosage:

100 μg/mL

Administration:

Intraperitoneal injection;100 μg/mL; every 48 hours; 20days

Result:

Suppressed the growth of advanced tumors.

CAS 號

375823-41-9

中文名稱

托珠單抗

運輸條件

Shipping with dry ice.

儲存方式

Please store the product under the recommended conditions in the Certificate of Analysis.